we assessed the lower urinary tract symptoms (luts) in prostatic cancer patients and investigated the sensitivity and specificity of international prostate symptom score (ipss) in the screening of these patients. a total number of 132 prostatic cancer patients as the case group who were confirmed by the pathologists and 101 noncancerous men as the control group, aged 50 or older, responded to a...

background: in order to use international prostate symptom score (ipss) in the iranian population, a valid and reliable persian version of this questionnaire is required. to date, this version of ipss with those characteristics is not available. material and methods: for evaluation of the validity, the original version of ipss (english version) was translated into persian and after 3 weeks was ...

BACKGROUND The aim of this study was to investigate the correlation between incidence of lower urinary tract symptoms and erectile dysfunction in men aged ≥50 years. MATERIAL AND METHODS A cross-sectional study was performed in 1644 men aged >50 years in Beijing. The International Index of Erectile Function (IIEF)-5 and International Prostate Symptom Score were recorded for each patient. Pear...

Sunitinib is widely used to treat patients with advanced renal cell carcinoma; however, its influences on the prostate volume and lower urinary tract symptoms remain unclear. To investigate the influence of sunitinib on clinical findings of urinary tract, we recruited a total of 20 male patients with advanced renal cell carcinoma who are treated with sunitinib. We evaluated clinical findings du...

Objective: To evaluate the correlation of International Prostatic Symptom Score with Prostate Volume Benign Hyperplasia patients. Study Design: A Cross- out sectional study was done. Qualitative variables measured by Chi square test and quantitative ANOVA. Pearson & multinominal regression were applied. P value considered significant at <0.05. It conducted in a tertiary care hospital, Zi...

PURPOSE We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies. MATERIALS AND METHODS Men 50 years or older with an International Prostate Symptom Score of 13 or greater and peak urinary flow rate of 4 to 15 ml per second received placebo or 8 mg silodosin daily with breakfast for 12 weeks. ...